The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease.


Dursun E. , Gezen-Ak D. , Hanagasi H., Bilgic B., Lohmann E., Ertan S., ...More

Journal of neuroimmunology, vol.283, pp.50-7, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 283
  • Publication Date: 2015
  • Doi Number: 10.1016/j.jneuroim.2015.04.014
  • Title of Journal : Journal of neuroimmunology
  • Page Numbers: pp.50-7
  • Keywords: Alzheimer's disease, Mild cognitive impairment (MCI), Parkinson's disease (PD), Interleukin 1 alpha (IL-1 alpha), Interleukin 1 beta (IL-1 beta), Interleukin 6 (IL-6), Alpha-2 macroglobulin (alpha 2-macroglobulin), Tumor necrosis factor alpha (TNF alpha), Brain derived neurotrophic factor (BDNF), Interleukin 10 (IL-10), Heat shock protein 90 (Hsp90), Biomarker, NECROSIS-FACTOR-ALPHA, CEREBROSPINAL-FLUID, VASCULAR DEMENTIA, TNF-ALPHA, PLASMA-LEVELS, INFLAMMATORY MARKERS, CYTOKINES, IL-1-BETA, BRAIN, ALPHA(1)-ANTICHYMOTRYPSIN

Abstract

Alzheimer's disease (EOAD, LOAD), mild cognitive impairment (MCI), Parkinson's disease (PD) and healthy controls were included to determine the serum interleukin-Is (IL-1 alpha, IL-1 beta), IL-6 and alpha-2-macroglobulin (alpha M-2) levels using ELISA.